Clinical Trials Logo

Phase 1 clinical trials

View clinical trials related to Phase 1.

Filter by:

NCT ID: NCT02634489 Completed - Healthy Clinical Trials

EC905 Pharmacokinetic Profile Study

Start date: March 2009
Phase: Phase 1
Study type: Interventional

A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.

NCT ID: NCT02010944 Completed - Healthy Subjects Clinical Trials

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Start date: September 2012
Phase: Phase 1
Study type: Interventional

This study compares the pharmacokinetics (PK), safety and tolerability of fixed dose combination (FDC) tablets containing solifenacin succinate and mirabegron with the co-administration of single entity tablets (SET), at three dose strengths.

NCT ID: NCT01415102 Completed - Pharmacokinetics Clinical Trials

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.

Start date: September 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study in healthy people is to evaluate safety, toleration and time course of plasma concentration of single inhaled doses of PF-05212372.

NCT ID: NCT01091532 Completed - Safety Clinical Trials

A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study in healthy people is to investigate the safety, toleration and time course of UK-396,082 concentration in the blood and any changes in relevant markers of drug effects, following multiple doses given twice daily by mouth for 14 days.